(Press-News.org) Natalie McCormick, PhD, of the Rheumatology and Allergy Clinical Epidemiology Research (RACER) Center within the Division of Rheumatology in the Mass General Brigham Department of Medicine, is the lead author of a paper published in Diabetes Care, “Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.”
Q: What challenges or unmet needs make this study important?
Gout, a type of inflammatory arthritis caused by a buildup of uric acid (urate) in the body, affects 5.1% of U.S. adults (over 12 million), including 10% of those aged 65 or older. Urate is produced by the body when breaking down compounds called purines and normally dissolves in the blood, but when levels are high, they can precipitate out as monosodium urate crystals which can deposit in the joints. In addition to acutely painful joint flares and damage, gout often occurs alongside cardiovascular-kidney-metabolic (CKM) conditions. For example, one in four U.S. adults with gout also has type 2 diabetes and this same statistic applies to gout and chronic kidney disease.
Conventional urate-lowering therapies (ULTs) are recommended for flare prevention, but they don’t help with the CKM comorbidities, making it necessary for patients with co-occurring conditions to take medications in different classes to treat both. This makes treatment decisions more complex, while increasing pill burden for patients and the potential for drug interactions.
Q: What central question(s) were you investigating?
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are approved for the treatment of type 2 diabetes, heart failure and chronic kidney disease, and have also been shown to decrease serum urate levels and the need for diuretic medications (a major risk factor for gout flares). Therefore, we wondered, could SGLT2i use by patients with gout reduce their need for conventional ULTs and acute flare medications, including NSAIDs, colchicine and high-dose glucocorticoids?
The latter would be particularly attractive since patients with gout tend to be at high risk for the cardiovascular, gastrointestinal, kidney and metabolic adverse effects of these flare medications.
Q: What methods or approach did you use?
We emulated a randomized clinical trial using large, population‑based datasets. We captured over 18,000 patients with diagnoses of gout and type 2 diabetes who filled a new prescription for a glucose-lowering treatment—either SGLT2i, dipeptidyl peptidase 4 inhibitors (DPP-4i) or glucagon-like peptide 1 receptor agonists (GLP1-RA)—and were not currently using ULTs.
We used statistical techniques to balance baseline characteristics between treatment groups (for example, demographics, number of recent gout flares, etc.), thus mimicking randomization. We then followed patients over time to compare the probability of individuals in each treatment arm starting ULTs, as well as rates of gout flares and prescriptions for gout flare treatments and diuretics.
Q: What did you find?
Compared to DPP-4i, SGLT2i use was associated with a 38% lower probability of starting allopurinol, a common urate-lowering drug. Patients using SGLT2i had fewer prescriptions for NSAIDs, colchicine and high-dose glucocorticoids, and had fewer gout flares. They also had fewer prescriptions for diuretic medications, especially loop diuretics. These findings were consistent in different sensitivity analyses, including when comparing SGLT2i to GLP1-RA, and in a repeat analysis in an external dataset.
Q: What are the real-world implications, particularly for patients?
Our findings hold promise for those living with gout and type 2 diabetes (and for clinicians treating them). SGLT2i use could reduce their exposure to NSAIDs and glucocorticoids, which often have adverse effects, by lowering their use of gout-related medications. More broadly, SGLT2i use may streamline care for this patient population and reduce their medication burden.
Q: How might you build on these findings?
While undertaking this study, it was fascinating to learn more about polypharmacy (typically defined as regularly taking at least five medications), including how it’s measured, its prevalence, the implications and potential ways it can be addressed. Polypharmacy hasn’t been well studied in gout, so that’s an avenue I’d like to pursue further in the future.
Authorship: In addition to McCormick, Mass General Brigham authors include Chio Yokose, Deborah Wexler, Sharan Rai, Greg Challener, Ran Abuhasira and Hyon Choi.
Paper cited: McCormick N., et al. “Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.” Diabetes Care. DOI: 10.2337/dc25-1713
Funding: This work was supported by grants from the National Institutes of Health (NIH): (R00-AR080243) and (R01- AR065944).
Disclosures: McCormick, Burrack, Yokose, Lu, Rai, Challener, Aviña-Zubieta and Abuhasira have no disclosures. Wexler reports serving on Data Monitoring Committees for Novo Nordisk. In the last 36 months, McCoy has received unrelated research support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), National Institute on Aging (NIA) of the NIH, Patient Centered Outcomes Research Institute (PCORI), National Center for Advancing Translational Sciences (NCATS) and the American Diabetes Association. She also served as a consultant to EmmiEducate® (Wolters Kluwer) and the Yale-New Haven Health System’s Center for Outcomes Research and Evaluation, and has received speaking honoraria and travel support from the American Diabetes Association. Choi reports research support from Horizon and LG Chem, and consulting fees from Ani, LG Chem, Horizon, Shanton and Protalix.
URL for CTA: https://diabetesjournals.org/care/article-abstract/doi/10.2337/dc25-1713/164377/Gout-Related-Medication-Use-After-Initiating?redirectedFrom=fulltext
END
Research spotlight: Use of glucose-lowering SGLT2i drugs may help patients with gout and diabetes take fewer medications
2026-02-02
ELSE PRESS RELEASES FROM THIS DATE:
Genetic system makes worker cells more resilient producers of nanostructures for advanced sensing, therapeutics
2026-02-02
Gas vesicles are among the largest known protein nanostructures produced and assembled inside microbial cells. These hollow, air-filled cylindrical nanostructures found in certain aquatic microbes have drawn increasing interest from scientists due to their potential for practical applications, including as part of novel diagnostic and therapeutic tools. However, producing gas vesicles is a hard ask for cells in the lab, hindering the development of applications.
In a recent study published in Nature Communications, a team of researchers led by Rice University bioengineer George Lu reports the development of a new genetic regulatory system to improve cell viability during the production ...
New AI model can assist with early warning for coral bleaching risk
2026-02-02
MIAMI — Scientists have created an AI model that forecasts moderate heat stress — a major precursor to coral bleaching — at sites along Florida’s Coral Reef up to six weeks ahead, with predictions generally accurate within one week.
The study presents a site-specific, explainable machine-learning framework to support coral scientists and restoration practitioners with local reef management and emergency response planning.
“This model gives coral scientists and resource managers advance notice of whether heat stress is likely to occur in a season — and, more importantly, ...
Highly selective asymmetric 1,6-addition of aliphatic Grignard reagents to α,β,γ,δ-unsaturated carbonyl compounds
2026-02-02
Scientists at Institute of Science Tokyo (Science Tokyo) have successfully realized the highly selective asymmetric 1,6-addition of aliphatic Grignard reagents to α,β,γ,δ-unsaturated carbonyl compounds. This new methodology employs an iron catalyst in combination with a chiral N-heterocyclic carbene ligand, which suppresses undesired side reactions and drives highly regio-, stereo-, and enantioselective alkyl migration. The achievement represents a major advance in organic synthesis, offering new opportunities for drug discovery, materials chemistry, and the fine-chemical sector.
In organic chemistry, ...
Black and Latino teens show strong digital literacy
2026-02-02
A study by UC Riverside and USC education scholars found that Black and Latino teens are significantly more adept than their white peers at detecting online disinformation—particularly content related to race and ethnicity.
These youth are not only quicker to identify false claims and racist propaganda, but also more likely to verify posts with credible sources and respond with corrective, fact-based content, the study found. According to the researchers, these skills are not being taught.
“This ...
Aging brains pile up damaged proteins
2026-02-02
As we age, we begin to lose the connections that wire up our brains—and neuroscientists aren’t sure why.
It is increasingly clear, though, that the loss of synapses—the flexible and adaptive relay stations central to our brains’ ability to think, learn, and remember—is central to the rise of cognitive decline and dementia in old age.
Now, researchers supported by the Knight Initiative for Brain Resilience have discovered clues that may tie synapse loss to another hallmark of brain aging: the declining ability of brain cells to break down and recycle damaged proteins.
Published January 21, 2026, in Nature, the study shows ...
Optimizing robotic joints
2026-02-02
Key Takeaways
Harvard SEAS researchers have developed a mathematical framework for optimizing the design of rolling contact joints, which are made of rolling surfaces and flexible connectors.
To demonstrate their method, they developed a knee-like joint that reduced misalignment by 99% compared with standard mechanisms, and a robotic gripper that could hold three times the weight of a conventionally designed gripper.
Consider the marvelous physics of the human knee. The largest hinge joint in the body, it has two rounded bones held together ...
Banning lead in gas worked. The proof is in our hair
2026-02-02
Prior to the establishment of the Environmental Protection Agency in 1970, Americans lived in communities awash with lead from industrial sources, paint, water supply pipes and, most significantly, tailpipe emissions. A dangerous neurotoxin that accumulates in human tissues and is linked to developmental deficits in children, environmental lead levels have come way down in the years since, and so have human exposures.
The proof is in your hair.
An analysis of hair samples conducted by University of Utah scientists show precipitous reductions in lead levels since 1916.
“We were able to show through our hair samples what the lead concentrations ...
Air pollution causes social instability in ant colonies
2026-02-02
Markus Knaden's Odor-guided Behavior research group at the Max Planck Institute for Chemical Ecology has been studying the effects of ozone on chemical communication in insects for some time. The research team was able to show that increased ozone levels alter the mating signal in fruit flies because ozone breaks down the carbon-carbon double bonds in the insects' sex pheromones. After male flies were exposed to ozone, they were no longer able to distinguish females from other males (see press release Air ...
Why we sleep poorly in new environments: A brain circuit that keeps animals awake
2026-02-02
You check into a hotel and toss and turn all night, but your sleep improves the following night. Scientists at Nagoya University wanted to understand why this happens. Working with mice, they have identified a group of neurons that become active when an animal enters a new environment. These neurons release a molecule called neurotensin that maintains wakefulness. The effect protects them from potential dangers in unknown surroundings. The study was published in Proceedings of the National Academy of Sciences.
This discovery may explain the "first ...
Some tropical land may experience stronger-than-expected warming under climate change
2026-02-02
Some tropical land regions may warm more dramatically than previously predicted, as climate change progresses, according to a new CU Boulder study that looks millions of years into Earth’s past.
Using lake sediments from the Colombian Andes, researchers revealed that when the planet warmed millions of years ago under carbon dioxide levels similar to today’s, tropical land heated up nearly twice as much as the ocean.
The study was published February 2 in the Proceedings of the National Academy of Sciences.
“The tropics are ...